News

The approval was based by data from over 2,700 subjects treated with peramivir in 27 clinical trials. University of Alabama Dr Richard Whitley said: "RAPIVAB is the first

Opdivo is a human programed death receptor-1 (PD-1) blocking antibody indicated to treat this skin cancer. The indication is approved under accelerated approval based on tumor response rate

This patent includes AC-201 or its pharmaceutically acceptable salts, active metabolite for treatment of type II diabetes. The patent also covers the methods of treatment using AC-201 for

"This is the second jurisdiction in which we have elected to file for Orphan Designation," said Dr. Brad Thompson , President and CEO of Oncolytics. "The EMA serves

L-Bcl-2 is a liposomal encapsulated oligonucleotide targeted to the translation initiation site of human Bcl-2 mRNA. The antisense oligonucleotide in L-Bcl-2 is a nuclease-resistant, hydrophobic analog of phosphodiesters

EpiVax and Novozymes Biopharma today announced that they have entered a license agreement for the development of novel treatments for autoimmune diseases. The agreement follows two years of

IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. IMBRUVICA (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton’s tyrosine

Under the deal, Tekmira’s Ebola drug will be made available in West Africa for clinical trials which are expected to start in early 2015. Funded by the Wellcome

The company said that around 78 patients will be enrolled in the randomized, double-blind, placebo controlled Phase II trial that will be conducted in the US, Europe and